Liontrust Reports 4.9235% Stake in MaxCyte
Liontrust Investment Partners reported 5,081,403 MaxCyte shares, equal to 4.9235% of the company, as of October 30, 2026. It filed a Schedule 13D on November 2.
Related stories
McEwen schedules Q3 2026 results conference call
M impact | EQUITY | Nov 02, 2026, 06:33 PM UTC
VCIG: Nasdaq trading halt continues — volatility pause (1:32 PM ET)
Nasdaq kept trading halted in VCIG (volatility pause) at 1:32 PM ET.
M impact | EQUITY | Nov 02, 2026, 06:32 PM UTC
US session market picture: S&P 500 +0.34%, Nasdaq 100 +0.05%; EUR/USD +0.32%, WTI -7.92%, WBD leads volume
US session market picture. US index futures: S and P futures is up 0.34 percent, Nasdaq futures is up 0.05 percent, Dow futures is up 1.02 percent and Russell futures is up 0.56 pe
M impact | EQUITY | Nov 02, 2026, 06:30 PM UTC
FTAI Aviation Shares Rise 7.2% After $1 Billion Note Offering
FTAI Aviation disclosed a $1 billion private offering of senior notes due 2034. The notes will be guaranteed by the company and other subsidiaries. Shares rose 7.2% to $200.47 on M
M impact | EQUITY | Nov 02, 2026, 06:29 PM UTC
Edwards Lifesciences Says PASCAL System Meets CLASP II TR Study Goal
Edwards Lifesciences said its PASCAL tricuspid repair system met the main goal in the CLASP II TR study.
L impact | EQUITY | Nov 02, 2026, 06:29 PM UTC
US Equity Indexes Rise Amid Sinking Crude Oil
M impact | EQUITY | Nov 02, 2026, 06:25 PM UTC